Loran O B, Dunaevskiĭ Ia L, Segal A S
Urol Nefrol (Mosk). 1996 Nov-Dec(6):37-9.
16 males with benign prostatic hyperplasia (BPH) stage I-II received extremely high-frequency (EHF) therapy alone (group 1), 47 BPH males stage I-II and chronic nonspecific prostatitis EHF therapy plus antibacterial drugs (group 2). Group 3 was control. Clinical pretreatment parameters in group 1 averaged: IPSS--16.6; QOL--4.1; Qmax--7.2 ml/s, RU-135 ml. Three to six months of treatment brought the improvement: IPSS--14.7; QOL--3.2. Qmax rose to 8.3 ml/s, residual urine decreased to 126 ml in 11 (68.7%) patients. The effectiveness of the 2 group treatment was higher: initial IPSS--18.3, QOL-4.5, Qmax--9.2 ml/s, RU--62 ml changed for IPSS--14.1, QOL--3.1 in 43(91.5%) patients, obstruction diminished in 31 (65.9%) patients (Qmax--10.2 ml/s, RU--53 ml). EHF therapy proved effective and safe in BPH alone and especially in BPH combination with chronic nonspecific prostatis.
16名患有I-II期良性前列腺增生（BPH）的男性仅接受极高频（EHF）治疗（第1组），47名I-II期BPH男性和慢性非特异性前列腺炎患者接受EHF治疗加抗菌药物（第2组）。第3组为对照组。第1组临床治疗前参数平均为：国际前列腺症状评分（IPSS）——16.6；生活质量评分（QOL）——4.1；最大尿流率（Qmax）——7.2毫升/秒，残余尿量（RU）——135毫升。三到六个月的治疗带来了改善：IPSS——14.7；QOL——3.2。Qmax升至8.3毫升/秒，11名（68.7%）患者的残余尿量降至126毫升。第2组治疗效果更高：初始IPSS——18.3，QOL——4.5，Qmax——9.2毫升/秒，RU——62毫升，43名（91.5%）患者变为IPSS——14.1，QOL——3.1，31名（65.9%）患者梗阻减轻（Qmax——10.2毫升/秒，RU——53毫升）。EHF治疗在单纯BPH中，尤其是在BPH合并慢性非特异性前列腺炎中被证明是有效且安全的。
